Cingulate Inc.CING
Key ratios
ROA
-83.3%2025
2024
-106.5%2023
-191.0%
ROE
-450.6%2025
2024
-5651.0%
Recent news
Shane Schaffer, Cingulate Chairman & CEO to Present "SMART Launch" Approach at Indegene Digital Summit
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
Track CING in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer